| Literature DB >> 28251611 |
Sarah L Smithson1, Marius Rademaker2, Susan Adams3, Stuart Bade4, Philip Bekhor1, Samantha Davidson4, Amanda Dore4, Catherine Drummond5, Gayle Fischer6, Alexander Gin1, Claire Grills1, Anne Halbert7, Zerina Lokmic8, Emma McCahon9, Vanessa A Morgan1, Dedee F Murrell10, David Orchard1, Anthony Penington1, Diana Purvis11, John Relic12, Susan Robertson1, Aaron J Robinson1, Laura Scardamaglia1, John Su1, Swee Tan13, Orli Wargon14, Lachlan Warren15, Li-Chuen Wong9, Tania Zappala4, Roderic Phillips1.
Abstract
Although most infantile haemangiomas do not require treatment due to a natural history of spontaneous involution, some require early intervention. The Australasian Vascular Anomalies Network and the Australasian Paediatric Dermatology Network have developed a consensus statement for the treatment of infantile haemangiomas with oral propranolol. Infants with haemangiomas that are life threatening, at risk of ulceration, or at risk of causing a significant functional impairment, psychological impact or physical deformity should be treated early with oral propranolol. Oral propranolol is safe and effective and in most healthy infants oral propranolol can be started in an outpatient setting.Entities:
Keywords: Australian; New Zealand; beta-blocker; consensus; hemangioma; infantile haemangioma; propranolol; vascular anomaly
Mesh:
Substances:
Year: 2017 PMID: 28251611 DOI: 10.1111/ajd.12600
Source DB: PubMed Journal: Australas J Dermatol ISSN: 0004-8380 Impact factor: 2.875